258 related articles for article (PubMed ID: 34365980)
41. Immune checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise Criteria.
Wintersperger BJ; Calvillo-Argüelles O; Lheureux S; Houbois CP; Spreafico A; Bedard PL; Neilan TG; Thavendiranathan P
Eur Heart J Case Rep; 2022 Jan; 6(1):ytab478. PubMed ID: 35079688
[TBL] [Abstract][Full Text] [Related]
42. Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors.
Furukawa A; Tamura Y; Taniguchi H; Kawamura A; Nagase S; Hayashi A; Tada Y; Sase K; Hatake K
J Cardiol; 2023 Jan; 81(1):63-67. PubMed ID: 35953399
[TBL] [Abstract][Full Text] [Related]
43. Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series.
Coustal C; Vanoverschelde J; Quantin X; Lesage C; Michot JM; Lappara A; Ederhy S; Assenat E; Faure M; Issa N; Lambotte O; Puyade M; Dereure O; Tosi D; Rullier P; Serre I; Larcher R; Klouche K; Chanques G; Vernhet-Kovacsik H; Faillie JL; Agullo A; Roubille F; Guilpain P; Maria ATJ
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258037
[TBL] [Abstract][Full Text] [Related]
44. Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment.
Wang C; Lin J; Wang Y; Hsi DH; Chen J; Liu T; Zhou Y; Ren Z; Zeng Z; Cheng L; Ge J
Front Pharmacol; 2021; 12():770631. PubMed ID: 34938185
[No Abstract] [Full Text] [Related]
45. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
[TBL] [Abstract][Full Text] [Related]
46. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
47. Immune Checkpoint Inhibitor-Induced Pure Red Cell Aplasia: A Review of 2 Cases in Metastatic Melanoma.
Rueda Prada L; Gavrancic T; Cadena Sanabria MO; Dumic I; Bourgeois K; King RL; Yan Y
Am J Case Rep; 2023 Nov; 24():e941789. PubMed ID: 37957950
[TBL] [Abstract][Full Text] [Related]
48. Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis.
Quinaglia T; Gongora C; Awadalla M; Hassan MZO; Zafar A; Drobni ZD; Mahmood SS; Zhang L; Coelho-Filho OR; Suero-Abreu GA; Rizvi MA; Sahni G; Mandawat A; Zatarain-Nicolás E; Mahmoudi M; Sullivan R; Ganatra S; Heinzerling LM; Thuny F; Ederhy S; Gilman HK; Sama S; Nikolaidou S; Mansilla AG; Calles A; Cabral M; Fernández-Avilés F; Gavira JJ; González NS; García de Yébenes Castro M; Barac A; Afilalo J; Zlotoff DA; Zubiri L; Reynolds KL; Devereux R; Hung J; Picard MH; Yang EH; Gupta D; Michel C; Lyon AR; Chen CL; Nohria A; Fradley MG; Thavendiranathan P; Neilan TG
JACC Cardiovasc Imaging; 2022 Nov; 15(11):1883-1896. PubMed ID: 36357131
[TBL] [Abstract][Full Text] [Related]
49. Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature.
Bi H; Ren D; Wang Q; Ding X; Wang H
Ann Palliat Med; 2021 Jan; 10(1):793-802. PubMed ID: 33545801
[TBL] [Abstract][Full Text] [Related]
50. Review: Treatment of immune checkpoint inhibitor-associated myocarditis.
Heemelaar JC; Antoni ML; Neilan TG
J Cardiovasc Pharmacol; 2023 Aug; ():. PubMed ID: 37506676
[TBL] [Abstract][Full Text] [Related]
51. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors.
Dolladille C; Ederhy S; Allouche S; Dupas Q; Gervais R; Madelaine J; Sassier M; Plane AF; Comoz F; Cohen AA; Thuny FR; Cautela J; Alexandre J
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31988143
[TBL] [Abstract][Full Text] [Related]
52. Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor-Induced Myocarditis.
Vasbinder A; Chen Y; Procureur A; Gradone A; Azam TU; Perry D; Shadid H; Anderson E; Catalan T; Blakely P; Nelapudi N; Fardous M; Bretagne MC; Adie SK; Pogue KT; Leja M; Yentz S; Schneider B; Fecher LA; Lao CD; Salem JE; Hayek SS
JACC CardioOncol; 2022 Dec; 4(5):689-700. PubMed ID: 36636441
[TBL] [Abstract][Full Text] [Related]
53. Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review.
Lehmann LH; Cautela J; Palaskas N; Baik AH; Meijers WC; Allenbach Y; Alexandre J; Rassaf T; Müller OJ; Aras M; Asnani AH; Deswal A; Laufer-Perl M; Thuny F; Kerneis M; Hayek SS; Ederhy S; Salem JE; Moslehi JJ
JAMA Cardiol; 2021 Nov; 6(11):1329-1337. PubMed ID: 34232253
[TBL] [Abstract][Full Text] [Related]
54. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
[TBL] [Abstract][Full Text] [Related]
55. Immune Checkpoint Inhibitor-Related Myocarditis: Recognition, Surveillance, and Management.
Kuhnly NM; Coviello J
Clin J Oncol Nurs; 2022 Feb; 26(1):54-60. PubMed ID: 35073300
[TBL] [Abstract][Full Text] [Related]
56. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China.
Wang F; Sun X; Qin S; Hua H; Liu X; Yang L; Yang M
Chin Clin Oncol; 2020 Apr; 9(2):16. PubMed ID: 32279526
[TBL] [Abstract][Full Text] [Related]
57. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.
Harvey C; Nahar KJ; McKeown J; Lo SN; Farag S; Yousaf N; Young K; Tas L; Meerveld-Eggink A; Blank C; Thomas A; McQuade J; Schilling B; Johnson DB; Huertas RM; Arance A; Lee J; Zimmer L; Long GV; Carlino MS; Wang Y; Menzies AM
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38296594
[TBL] [Abstract][Full Text] [Related]
58. Myocarditis Induced by Immunotherapy in Metastatic Melanoma-Review of Literature and Current Guidelines.
Czarnecka AM; Kleibert M; Płachta I; Rogala P; Wągrodzki M; Leszek P; Rutkowski P
J Clin Med; 2022 Sep; 11(17):. PubMed ID: 36079112
[TBL] [Abstract][Full Text] [Related]
59. Cardiac MRI Features and Prognostic Value in Immune Checkpoint Inhibitor-induced Myocarditis.
Cadour F; Cautela J; Rapacchi S; Varoquaux A; Habert P; Arnaud F; Jacquier A; Meilhac A; Paganelli F; Lalevée N; Scemama U; Thuny F
Radiology; 2022 Jun; 303(3):512-521. PubMed ID: 35230185
[TBL] [Abstract][Full Text] [Related]
60. Cardiovascular events after cancer immunotherapy as oncologic emergencies: Analyses of 610 head and neck cancer patients treated with immune checkpoint inhibitors.
Reyes-Gibby CC; Qdaisat A; Ferrarotto R; Fadol A; Bischof JJ; Coyne CJ; Lipe DN; Hanna EY; Shete S; Abe JI; Yeung SJ
Head Neck; 2024 Mar; 46(3):627-635. PubMed ID: 38151809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
